Arnd Hoburg1, Philipp Niemeyer2,3, Volker Laute4, Wolfgang Zinser5, Christoph Becher6, Thomas Kolombe7, Jakob Fay8, Stefan Pietsch9, Tomasz Kuźma10, Wojciech Widuchowski11, Stefan Fickert12,13. 1. Med Center 360 degree Berlin, Kieler Straße 1, 12163, Berlin, Germany. arnd.hoburg@med360grad.de. 2. Department of Orthopedic Surgery and Traumatology, University Hospital, Freiburg, Germany. 3. OCM Clinic, Munich, Germany. 4. Med Center 360 degree Berlin, Kieler Straße 1, 12163, Berlin, Germany. 5. Department of Orthopedic Surgery and Traumatology, St. Vinzenz-Hospital, Dinslaken, Germany. 6. Department of Orthopedic Surgery, Medical University Annastift, Hannover, Germany. 7. Traumatology and Reconstructive Surgery, DRK Hospital, Luckenwalde, Germany. 8. Department of Traumatology and Arthroscopic Surgery, Lubinus Clinicum, Kiel, Germany. 9. Department of Orthopedic Surgery and Traumatology, Rudolf Elle Hospital, Eisenberg, Germany. 10. Department of Orthopedic Surgery and Traumatology, Center of Sports Medicine, Orthopedic Clinic, Warsaw, Poland. 11. Hospital of Orthopedics and Trauma Surgery, Piekary Slaskie, Poland. 12. Sporthopaedicum Straubing, Straubing, Germany. 13. Department of Orthopedic Surgery and Traumatology, Medical Faculty Mannheim, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany.
Abstract
PURPOSE: To evaluate the safety and efficacy of matrix-associated autologous chondrocyte implantation (ACI) using spheroids in comparison to arthroscopic microfracture for the treatment of symptomatic cartilage defects of the knee. METHODS: In a prospective multicenter-controlled trial, patients aged between 18 and 50 years, with single symptomatic focal cartilage defects between 1 and 4 cm2 (mean 2.6 ± 0.8, median 2.75, range 1.44-5.00) in the knee were randomized to treatment with ACI with spheroids (n = 52) or microfracture (n = 50). Primary clinical outcome was assessed by the Knee Injury and Osteoarthritis Outcome Score (KOOS). Analyses were performed in a defined hierarchical manner where outcomes of ACI were first compared to baseline values followed by a comparison to the microfracture group with repeated-measures ANCOVA with a non-inferiority approach. Subgroup analyses were performed to investigate the influence of age and defect size on the overall KOOS. Secondary clinical outcomes were the magnetic resonance observation of cartilage repair tissue (MOCART), modified Lysholm score and International Knee Documentation Committee (IKDC) examination form. Safety data focused on adverse events. Here the 5 years results are presented at which there were 33 observed cases in the ACI group and 30 in the microfracture group. RESULTS: The overall KOOS and its five subscores were significantly improved compared to baseline for both the ACI and microfracture group. Non-inferiority of ACI to microfracture was confirmed for the overall KOOS and the subscores, while for the subscores activities of daily living, quality of life and sports and recreation of the threshold for superiority was passed. In the ACI group, a notably more rapid initial improvement of the KOOS was found at three months for the older age group compared to the younger age group and the microfracture group. No other differences were found based on age or defect size. In addition, clinical improvement was found for the MOCART, modified Lysholm and IKDC examination form both the ACI and microfracture group. No safety concern related to either treatment was observed. CONCLUSION: This study confirms the safety and efficacy of matrix-associated ACI with spheroids at a mid to long-term follow-up. Non-inferiority of ACI to microfracture was confirmed for the overall KOOS and all subscores, while superiority was reached for the subscores activities of daily living, quality of life and sports and recreation in the ACI group. This underlines the importance of ACI for the young and active patients. LEVEL OF EVIDENCE: I.
PURPOSE: To evaluate the safety and efficacy of matrix-associated autologous chondrocyte implantation (ACI) using spheroids in comparison to arthroscopic microfracture for the treatment of symptomatic cartilage defects of the knee. METHODS: In a prospective multicenter-controlled trial, patients aged between 18 and 50 years, with single symptomatic focal cartilage defects between 1 and 4 cm2 (mean 2.6 ± 0.8, median 2.75, range 1.44-5.00) in the knee were randomized to treatment with ACI with spheroids (n = 52) or microfracture (n = 50). Primary clinical outcome was assessed by the Knee Injury and Osteoarthritis Outcome Score (KOOS). Analyses were performed in a defined hierarchical manner where outcomes of ACI were first compared to baseline values followed by a comparison to the microfracture group with repeated-measures ANCOVA with a non-inferiority approach. Subgroup analyses were performed to investigate the influence of age and defect size on the overall KOOS. Secondary clinical outcomes were the magnetic resonance observation of cartilage repair tissue (MOCART), modified Lysholm score and International Knee Documentation Committee (IKDC) examination form. Safety data focused on adverse events. Here the 5 years results are presented at which there were 33 observed cases in the ACI group and 30 in the microfracture group. RESULTS: The overall KOOS and its five subscores were significantly improved compared to baseline for both the ACI and microfracture group. Non-inferiority of ACI to microfracture was confirmed for the overall KOOS and the subscores, while for the subscores activities of daily living, quality of life and sports and recreation of the threshold for superiority was passed. In the ACI group, a notably more rapid initial improvement of the KOOS was found at three months for the older age group compared to the younger age group and the microfracture group. No other differences were found based on age or defect size. In addition, clinical improvement was found for the MOCART, modified Lysholm and IKDC examination form both the ACI and microfracture group. No safety concern related to either treatment was observed. CONCLUSION: This study confirms the safety and efficacy of matrix-associated ACI with spheroids at a mid to long-term follow-up. Non-inferiority of ACI to microfracture was confirmed for the overall KOOS and all subscores, while superiority was reached for the subscores activities of daily living, quality of life and sports and recreation in the ACI group. This underlines the importance of ACI for the young and active patients. LEVEL OF EVIDENCE: I.
Authors: Gunnar Knutsen; Jon Olav Drogset; Lars Engebretsen; Torbjørn Grøntvedt; Tom C Ludvigsen; Sverre Løken; Eirik Solheim; Torbjørn Strand; Oddmund Johansen Journal: J Bone Joint Surg Am Date: 2016-08-17 Impact factor: 5.284
Authors: Alex C DiBartola; Joshua S Everhart; Robert A Magnussen; James L Carey; Robert H Brophy; Laura C Schmitt; David C Flanigan Journal: Knee Date: 2016-02-18 Impact factor: 2.199
Authors: Dieter Van Assche; Danny Van Caspel; Filip Staes; Daniel B Saris; Johan Bellemans; Johan Vanlauwe; Frank P Luyten Journal: Physiother Theory Pract Date: 2010-08-08 Impact factor: 2.279
Authors: James L Carey; Kevin G Shea; Anders Lindahl; Haris S Vasiliadis; Carl Lindahl; Lars Peterson Journal: Am J Sports Med Date: 2020-03-17 Impact factor: 6.202
Authors: Arnd Hoburg; Philipp Niemeyer; Volker Laute; Wolfgang Zinser; Christoph Becher; Thomas Kolombe; Jakob Fay; Stefan Pietsch; Tomasz Kuźma; Wojciech Widuchowski; Stefan Fickert Journal: Cartilage Date: 2020-01-01 Impact factor: 3.117